Current Psychiatry Reports

, Volume 3, Issue 6, pp 507–512 | Cite as

Residual neuropsychologic effects of cannabis

  • Harrison G. PopeJr.
  • Amanda J. Gruber
  • Deborah Yurgelun-Todd


Acute intoxication with cannabis clearly produces cognitive impairment, but it is less clear how long cognitive deficits persist after an individual stops regular cannabis use. Numerous methodologic difficulties confront investigators in the field attempting to assess the residual neuropsychologic effects of cannabis among heavy users, and these must be understood to properly evaluate available studies. At present, it appears safe to conclude that deficits in attention and memory persist for at least several days after discontinuing regular heavy cannabis use. Some of these deficits may be caused or exacerbated by withdrawal effects from the abrupt discontinuation of cannabis; these effects typically peak after 3 to 7 days of abstinence. It is less clear, however, whether heavy cannabis use can cause neurotoxicity that persists long after discontinuation of use. It seems likely that such long-term effects, if they exist, are subtle and not clinically disabling—at least in the majority of cases.


Ecstasy Cannabis User Heavy User Neuropsychologic Deficit Abrupt Discontinuation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Pope HG Jr, Gruber AJ, Yurgelun-Todd D: The residual neuropsychological effects of cannabis: the current status of research. Drug Alcohol Depend 1995, 38:25–34.PubMedCrossRefGoogle Scholar
  2. 2.
    Pope HG Jr, Gruber AJ, Hudson JI, et al.: Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001, In press. This is the largest recent study of the residual neuropsychologic effects of cannabis in long-term users.Google Scholar
  3. 3.
    Ashton CH: Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 2001, 178:101–106. A good, brief review of basic current knowledge about the pharmacology of cannabis.PubMedCrossRefGoogle Scholar
  4. 4.
    Hall W, Solowij N: Adverse effects of cannabis. Lancet 1998, 352:1611–1616. A good, brief review of the current state of knowledge on adverse effects of cannabis use.PubMedCrossRefGoogle Scholar
  5. 5.
    Gruber AJ, Pope HG, Jr: Cannabis-related disorders. In Psychiatry. Edited by Tasman A. Philadelphia: WB Saunders; 1996.Google Scholar
  6. 6.
    Jones RT, Benowitz NL, Herning RI: Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol 1981, 21:143S-152S.PubMedCrossRefGoogle Scholar
  7. 7.
    Kouri EM, Pope HG Jr, Lukas SE: Changes in aggressive behavior during withdrawal from long-term marijuana use. Psychopharmacology 1999, 143:302–308.PubMedCrossRefGoogle Scholar
  8. 8.
    Haney M, Ward AS, Comer SD, et al.: Abstinence symptoms following smoked marijuana in humans. Psychopharmacology 1999, 141:395–404.PubMedCrossRefGoogle Scholar
  9. 9.
    Kouri EM, Pope HG Jr: Abstinence symptoms during withdrawal from chronic marijuana use. Exp Clin Psychopharm 2000, 8:483–492. A review of existing studies and presentation of new data on the cannabis withdrawal syndrome.CrossRefGoogle Scholar
  10. 10.
    Pennington BE, Ozonoff S: Executive functions and developmental psychopathology. J Child Psychiatry Psychology 1996, 37:51–87.CrossRefGoogle Scholar
  11. 11.
    Barkley R: Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 1997, 121:65–94.PubMedCrossRefGoogle Scholar
  12. 12.
    Aronowitz B, Liebowitz M, Hollander E, et al.: Neuropsychiatric and neuropsychological findings in conduct disorder and attention-deficit hyperactivity disorder. J Neuropsychiatry 1994, 6:245–249.Google Scholar
  13. 13.
    Lueger RJ, Gill KJ: Frontal-lobe cognitive dysfunction in conduct disorder adolescents. J Clin Psychology 1990, 46:696–706.Google Scholar
  14. 14.
    Gorenstein EE: Cognitive-perceptual deficit in an alcoholism spectrum disorder. J Stud Alcohol 1987, 48:310–318.PubMedGoogle Scholar
  15. 15.
    Morgan AB, Lilienfeld SO: A meta-analytic review of the relation between antisocial behavior and neuropsychological measures of executive function. Clin Psychology Rev 2000, 20:113–136.CrossRefGoogle Scholar
  16. 16.
    Williamson P: Hypofrontality in schizophrenia: a review. Can J Psychiatry 1987, 32:399–404.PubMedGoogle Scholar
  17. 17.
    Cantwell R, Brewin J, Glazebrook C, et al.: Prevalence of substance misuse in first-episode psychosis. Br J Psychiatry 1999, 174:150–153.PubMedCrossRefGoogle Scholar
  18. 18.
    Bray JW, Zarkin GA, Ringwalt C, et al.: The relationship between marijuana initiation and dropping out of high school. Health Econ 2000, 9:9–18.PubMedCrossRefGoogle Scholar
  19. 19.
    Levin ED, Rezvani AH: Development of nicotinic drug therapy for cognitive disorders. Eur J Pharmacol 2000, 393:141–146.PubMedCrossRefGoogle Scholar
  20. 20.
    Yurgelun-Todd DA, Gruber SA, Hanson RA, et al.: Residual effects of marijuana use: an fMRI study. Paper presented at: 60th Annual Meeting College on Problems of Drug Dependence; Scottsdale, AZ, June 1998.Google Scholar
  21. 21.
    Block RI, Ghoneim MM: Effects of chronic marijuana use on human cognition. Psychopharmacology 1993, 110:219–228.PubMedCrossRefGoogle Scholar
  22. 22.
    Pope HG Jr, Yurgelun-Todd D: The residual cognitive effects of heavy marijuana use in college students. JAMA 1996, 275:521–527.PubMedCrossRefGoogle Scholar
  23. 23.
    Fletcher JM, Page B, Francis DJ, et al.: Cognitive correlates of long-term cannabis use in Costa Rican men. Arch Gen Psychiatry 1996, 53:1051–1057.PubMedGoogle Scholar
  24. 24.
    Croft RJ, Mackay AJ, Mills ATD, Gruzelier JGH: The relative contributions of ecstasy and cannabis to cognitive impairment. Psychopharmacology 2001, 153:373–379.PubMedCrossRefGoogle Scholar
  25. 25.
    Struve FA, Straumanis JJ, Patrick G, et al.: Topographic quantitative EEG sequelae of chronic marihuana use: A replication using medically and psychiatrically screened normal subjects. Drug Alcohol Dep 1999, 556:167–179.CrossRefGoogle Scholar
  26. 26.
    Patrick G, Struve FA: Reduction of auditory P50 gating response in marihuana users: further supporting data. Clin Electroencephalography 2000, 31:88–93.Google Scholar
  27. 27.
    Patrick G, Straumanis JJ, Struve FA, et al.: Early and middle latency evoked potentials in medically and psychiatrically normal daily marihuana users: a paucity of significant findings. Clin Electroencephalography 1997, 28:26–31.Google Scholar
  28. 28.
    Solowij N: Cannabis and Cognitive Functioning. Cambridge, UK: Cambridge University Press; 1998. A comprehensive review of the previous literature, together with extensive new data suggesting possible long-term residual effects in heavy cannabis users.Google Scholar
  29. 29.
    Schwartz RH, Gruenewald PJ, Klitzner M, et al.: Short-term memory impairment in cannabis-dependent adolescents. Am J Dis Child 1989, 143:1214–1219.PubMedGoogle Scholar
  30. 30.
    Lyketsos CG, Garrett E, Liang KY, Anthony JC: Cannabis use and cognitive decline in persons under 65 years of age. Am J Epidemiology 1999, 149:794–800.Google Scholar
  31. 31.
    Ehrenreich H, Rinn T, Kunert HJ, et al.: Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology 1999, 142:295–301.PubMedCrossRefGoogle Scholar
  32. 32.
    Rodgers J: Cognitive performance amongst recreational users of ecstasy. Psychpharmacology 2000, 151:19–24.CrossRefGoogle Scholar
  33. 33.
    Struve FA, Patrick G, Straumanis JJ, et al.: Possible EEG sequalae of very long duration marihuana use: pilot findings from topographic quantitative EEG analysis of subjects with 15 to 24 years of cumulative daily exposure to THC. Clin Electroencephalography 1998, 29:31–36.Google Scholar

Copyright information

© Current Science Inc 2001

Authors and Affiliations

  • Harrison G. PopeJr.
    • 1
  • Amanda J. Gruber
    • 1
  • Deborah Yurgelun-Todd
    • 1
  1. 1.Department of PsychiatryMcLean Hospital/Harvard Medical SchoolBelmontUSA

Personalised recommendations